Journal of Personalized Medicine, Volume 15, Issue 2
2025 February - 37 articles
Cover Story: Cancer therapy has advanced significantly with chemotherapy, targeted therapies, and immunotherapies, yet drug resistance remains a formidable challenge. Resistant cancer cells undergo metabolic reprogramming, shifting from glycolysis to oxidative phosphorylation (OXPHOS) and exploiting alternative fuels like glutamine. These adaptations sustain tumor growth and enable immune evasion by increasing reactive oxygen species (ROS) and immune checkpoints such as PD-L1. This review explores targeting metabolic vulnerabilities, particularly in glycolysis, glutamine metabolism, and the kynurenine pathway, in order to enhance therapeutic efficacy. Combining metabolic inhibitors with an immune checkpoint blockade presents a promising strategy to overcome resistance and improve cancer outcomes. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.